advertisement
Gabrielle PH 32
Showing records 1 to 25 | Display all abstracts from Gabrielle PH98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Bhandari S
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Hunt AR
British Journal of Ophthalmology 2023; 107: 842-848
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Arnould L
Journal of clinical medicine 2022; 11:
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Gabrielle PH
Ophthalmology and therapy 2022; 11: 797-810
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Seydou A
Journal of clinical medicine 2022; 11:
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Nguyen V
British Journal of Ophthalmology 2023; 107: 842-848
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Binquet C
Journal of clinical medicine 2022; 11:
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Nguyen V
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Arnold JJ
British Journal of Ophthalmology 2023; 107: 842-848
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Gabrielle PH
Journal of clinical medicine 2022; 11:
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
McAllister IL
British Journal of Ophthalmology 2023; 107: 842-848
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Daien V; Viola F
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Mehta H
British Journal of Ophthalmology 2023; 107: 842-848
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Chamard C
Journal of clinical medicine 2022; 11:
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Viola F
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Invernizzi A
British Journal of Ophthalmology 2023; 107: 842-848
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Bretillon L
Journal of clinical medicine 2022; 11:
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Bougamha W; Young S
Ophthalmology and therapy 2022; 11: 797-810
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Bron AM
Journal of clinical medicine 2022; 11:
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Ponsioen T
British Journal of Ophthalmology 2023; 107: 842-848
99389 Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study
Acar N
Journal of clinical medicine 2022; 11:
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Romero-Nuñez B
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Gabrielle PH
British Journal of Ophthalmology 2023; 107: 842-848
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Figueras-Roca M
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
O'Toole L
British Journal of Ophthalmology 2023; 107: 842-848
